Re-Vana Therapeutics develops biodegradable ocular implants using patented photo-crosslinked technology for sustained intraocular release of biologics and small-molecule drugs over six months. This approach addresses the need for reduced frequency of drug administration in patients with sight-threatening diseases, enhancing treatment adherence and patient outcomes.
Funding
$16.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VVFounders
Product
Problem
Current treatments for sight-threatening diseases often require frequent drug administrations, leading to poor patient adherence and suboptimal outcomes. This is due to the rapid clearance of traditional eye drops and injections, which necessitates repeated clinical visits and can increase the risk of complications.
Solution
Re-Vana Therapeutics develops sustained-release ocular implants designed to deliver biologics and small-molecule drugs directly into the eye over a period of six months or longer. The company's patented photo-crosslinked technology enables the creation of biodegradable implants with adjustable drug-release rates, ranging from 0.1 µg/day to over 4 µg/day, depending on the specific therapeutic and target disease. Re-Vana offers two primary implant platforms: EyeLief, a pre-formed implant suitable for a range of APIs, and OcuLief, an in-situ forming implant designed for biologics requiring higher release rates. These technologies aim to reduce the frequency of drug administration, improve patient compliance, and enhance the overall quality of care for individuals with chronic ophthalmic conditions. By partnering with pharmaceutical companies, Re-Vana seeks to integrate its drug-delivery systems with next-generation therapeutics.
Target Audience
Re-Vana's primary customers are pharmaceutical companies seeking advanced drug-delivery systems for their ophthalmic therapeutics, as well as clinicians treating patients with sight-threatening diseases.
Features
- EyeLief: Pre-formed, photo-crosslinked biodegradable implant for sustained intraocular release of APIs up to 6 months.
- EyeLief-SD: Variant of EyeLief enabling API release up to 6 months at elevated rates (0.625 µg/day to 2 µg/day), suited for biologics and peptides.
- OcuLief: In-situ forming implant system involving injection of a gel that undergoes phase inversion and photo-crosslinking, enabling sustained release for 6-12 months.
- Adjustable API release rates achieved by altering implant polymers, photo-crosslinking degree, crosslink density, API loading, and implant dimensions.
- Formulation interventions to regulate API release duration and rate, influencing degradation time.
- Narrow-gauge needle (25G/27G) injection for OcuLief, minimizing invasiveness.